Meara Murphy active positions
Companies | Position | Start | End |
---|---|---|---|
PEAR THERAPEUTICS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - |
Career history of Meara Murphy
Former positions of Meara Murphy
Companies | Position | Start | End |
---|---|---|---|
Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Public Communications Contact | 2011-09-28 | 2019-09-30 |
LANTHEUS HOLDINGS, INC. | Public Communications Contact | 2018-12-31 | 2019-09-30 |
Statistics
International
United States | 4 |
Operational
Public Communications Contact | 3 |
Investor Relations Contact | 1 |
Sectoral
Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
LANTHEUS HOLDINGS, INC. | Health Technology |
Private companies | 2 |
---|---|
Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Health Technology |
Pear Therapeutics, Inc.
Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Meara Murphy
- Experience